When does genomics become eugenics?
By Eben Kirksey,
Financial Review
| 12. 11. 2020
As the tools to identify human traits and manipulate them become more refined, ideas about normalcy and deviancy, fitness and disability, are subtly changing.
Simply Google “BGI NIFTY” and you will find a slick website from China’s premier genomics company offering new options in the quest for quality children. This screening technology has already been used in more than 62 countries in Asia, Europe, the Americas, and the Middle East.
The NIFTY webpage has a “decision calculator” to see if you should mitigate the risks of your pregnancy. An embedded YouTube video offers a perspective from a young white couple. They talk in British accents about the importance of accuracy, saying that they are willing to pay for the best prenatal care on the market. An older single woman says that this will be her first and perhaps only baby, and she wants to make sure that nothing is wrong.
Previously in China, under the controversial one-child policy, couples were encouraged to make the most of their only shot. Amniocentesis – the insertion of a needle through the abdominal skin into the uterus to extract amniotic fluid which is then tested – was promoted by government experts as part of the practice...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
